Nuclear heat shock protein 110 expression is associated with poor prognosis and hyperthermo-chemotherapy resistance in gastric cancer patients with peritoneal metastasis

Table 1 Relationship between clinicopathological characteristics of gastric cancer patients and nuclear heat shock protein 110 expression n (%)

Factors	HSP110 expression in gastric cancer patients (n = 14)
	Low (n = 5)	High (n = 9)	P value
Age (mean ± SE)	55.2 ± 3.8	59.3 ± 2.8	0.4025
Sex,
Male	2 (22.2)	7 (77.8)	0.1575
Female	3 (60.0)	2 (40.0)
Histology
Well, Moderate	1 (33.3)	2 (66.7)	0.9227
Muc, Poor, Signet	4 (36.4)	7 (63.6)
Depth
sm, mp, ss	0 (0.0)	0 (0.0)
se, si	5 (35.7)	9 (64.3)
Lymph node metastasis
Absent	0 (0.0)	2 (100.0)	0.2549
Present	5 (41.7)	7 (58.3)
Lymphatic invasion
Absent	1 (33.3)	3 (66.7)	0.4797
Present	4 (40.0)	6 (60.0)
Venous invasion
Absent	4 (40.0)	6 (60.0)	0.5967
Present	1 (25.0)	3 (75.0)
Peritoneal lavage cytology
Negative	1 (25.0)	3 (75.0)	0.5967
Positive	4 (40.0)	6 (60.0)
Peritoneal metastasis
Absent	2 (50.0)	2 (50.0)	0.4805
Present	3 (30.0)	7 (70.0)

Well: Well-differentiated; Moderate: Moderately differentiated; Muc: Mucinous; Poor: Poorly differentiated; Signet: Signet ring cells; sm: Submucosa; mp: Muscularis propria; ss: Subserosa; se: Serosa exposed; si: Serosa infiltrating.